secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2025-08-01T23:59:59+00:00
Accession:  0001193125-25-171647
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Executive Chairman Harlan Waksal departs Lyra; CEO Palasis becomes Chair
------------------------------------------------------------------------

- Harlan W. Waksal's employment terminated effective August 1, 2025; he resigned from Board.
- Dr. Waksal eligible for severance per employment agreement upon signing separation and release.
- Maria Palasis, President & CEO, appointed Chair of the Board effective immediately.
- Jim Tobin remains as Lead Independent Director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000119312525171647/0001193125-25-171647-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000119312525171647/d949358d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-171647

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer